维普期刊资源整合服务平台（V6.5）

107篇 您的检索式：作者名="Link BK"

选中清除导出查看参考文献查看引证文献引用追踪共6页首页上一页第1页下一页末页 /6 跳转

	题名	作者	年代	出处	被引量
1	Vitamin D insufficiency andprognosis in non-Hodgkin's lymphoma 显示文摘	Drake MT Maurer MJ Link BK	2010	Clin Oncol2010，28，27：	1
2	Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:half of patients respond to a four-dose treatment program 显示文摘	Mclaughlin P Grillo-Lopez AJ Link BK	1998	J Clin Oncol1998，16，8：	1
3	Rituximab chimeric anti - CD20 monoclonal antibody therapy for relapsed indolent lymphoma: hald of patient respond to four - does treatment program 显示文摘	McLaughlin P Grillo - lopez A J Link BK	1998	J Clin Oncol1998，16，8：	1
4	Phase Ⅱ study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin' s lymphoma 显示文摘	Vose JM Link BK Grossbard ML	2001	J Clin Oncol2001，19，2：	1
5	Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program 显示文摘	McLaughlin P Grillo-Lopez A J Link BK	1998	J Clin Oncol1998，16，：	1
6	Monoclonal antibody therapy of B cell lymphoma显示文摘	Weiner GJ Link BK	2004	Expert Opin Biol Ther2004，4，：	1
7	Rituximab chimericanti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: halfof patients respond to a four-dose treatment program显示文摘	McLaughlin P Grillo-Lopez AJ Link BK	1998	Clin Oncol1998，16，：	1
8	Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:half of patients respond to a four-dose treatment program显示文摘	MCLAUGHLIN P GRILLO-LOPEZ AJ LINK BK	1998	J Clin Oucol1998，16，8：	1
9	Bile acid conjugates ofa nonsteroidal glucocorticoid receptor modulator 显示文摘	TU N LINK JT SORENSEN BK	2004	Bioorg MedChem Lett2004，14，16：	1
10	Anti-CD20 monoclonal an- tibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab 显示文摘	Bowles JA Wang SY Link BK	2006	Blood2006，108，8：	1
11	Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:half of patients respond to a four-dose treatment program显示文摘	McLaughlin P Grillo-Lopez AJ Link BK	1998	J Clin Oncol1998，16，8：	1
12	Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program 显示文摘	McLaughlin P Grillo-Lopez A J Link BK	1998	J Clin Oncol1998，16，8：	1
13	Long term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated,aggressive non Hodgk in lvmphoma显示文摘	Vose JM Link BK Grossbard MI	2005	Leuk Lymphoma2005，46，11：	1
14	Rituximab chimeric antiCD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program 显示文摘	McLaughlin P Grillo-Lopez AJ Link BK	1998	J Clin Oncol1998，16，8：	1
15	Vitamin D insuffi-ciency and prognosis in non-Hodgkin's lymphoma 显示文摘	Drake MT Maurer MJ Link BK	2010	ClinOncol2010，28，27：	1
16	Phase II study of ritux-imab in combination with CHOP chemotherapy in patients with pre-viously untreated,aggressive non Hodgkin lymphoma(NHL)显示文摘	Vose JM Link BK Grossbard ML	2001	J Clin Oncol2001，19，：	1
17	Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile显示文摘	Tien YY Link BK Brooks JM	2015	Leuk Lymphoma2015，56，1：	1
18	Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer 显示文摘	Lubaroff DM Konety B Link BK	2006	Hum Gene Ther2006，17，：	1
19	Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated,aggressive non-Hodgkin's lymphoma显示文摘	Vose JM Link BK Grossbard ML		0，，：	1
20	PhaseⅡstudy of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma显示文摘	Vose JM Link BK Grossbard ML	2001	J Clin Oncol2001，19，：	1

返回顶部每页显示：

共6页首页上一页第1页下一页末页 /6 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示